Magle Chemoswed Holding AB (publ) (STO: MAGLE)

Market Cap	416.88M
Revenue (ttm)	179.11M
Net Income (ttm)	7.70M
Shares Out	10.80M
EPS (ttm)	0.71
PE Ratio	54.18
Forward PE	30.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10
Open	38.60
Previous Close	38.60
Day's Range	38.60 - 38.60
52-Week Range	21.40 - 49.80
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 24, 2024

About MAGLE

Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, whic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1944
• Employees: 78
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: MAGLE

Financial Performance

In 2023, CLAV's revenue was 160.61 million, an increase of 12.55% compared to the previous year's 142.70 million. Losses were -65.35 million, -42.08% less than in 2022.